Compile Data Set for Download or QSAR
maximum 50k data
Found 495 of ic50 data for polymerid = 50006874
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558265(N-Methyl-3-[[methyl-[3-[[6-(1-H-pyrazol-5-yl)-3-py...)
Affinity DataIC50:  3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558426(Methyl 4-hydroxy-4-[3-[[6-(1-H-pyrazol-5-yl)-3-pyr...)
Affinity DataIC50:  3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558427(US11365192, Example 51-2)
Affinity DataIC50:  3.5nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558428(1-[4-Hydroxy-4-[3-[[6-(1-H-pyrazol-5-yl)-3-pyridin...)
Affinity DataIC50:  4.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558214(2,3-Difluoro-5-[3-[[6-(1H-pyrazol-5-yl)-3-pyridiny...)
Affinity DataIC50:  5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558439(N-Methyl-N-[[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]o...)
Affinity DataIC50:  5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558338(US11365192, Example 42-16)
Affinity DataIC50:  5.70nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558218(2-Methyl-5-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxyme...)
Affinity DataIC50:  6.20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558269(US11365192, Example 23-6)
Affinity DataIC50:  6.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591500(CHEMBL5195099)
Affinity DataIC50:  6.5nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558216(US11365192, Example 11-3)
Affinity DataIC50:  7.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558188(1-Acetyl-4-[8-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]ox...)
Affinity DataIC50:  7.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558158(US11365192, Example 1-63)
Affinity DataIC50:  8.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558529(US11365192, Example 72-6)
Affinity DataIC50:  9.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558440(1,1,1-Trifluoro-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyrid...)
Affinity DataIC50:  10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558219(US11365192, Example 12-2)
Affinity DataIC50:  11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558342(US11365192, Example 42-20)
Affinity DataIC50:  11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558339(US11365192, Example 42-17)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558326(US11365192, Example 42-4)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558533(1,1-Dioxo-3-[8-[6-(1H-pyrazol-5-yl)pyridin-3-yl]ox...)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558222(US11365192, Example 13-2)
Affinity DataIC50:  13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558527(US11365192, Example 72-4)
Affinity DataIC50:  14nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558332(US11365192, Example 42-10)
Affinity DataIC50:  15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591501(CHEMBL5183418)
Affinity DataIC50:  15nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558335(US11365192, Example 42-13)
Affinity DataIC50:  15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558431(US11365192, Example 53-2)
Affinity DataIC50:  16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558452(3-[[6-(4-Chloro-1H-pyrazol-5-yl)-3-pyridinyl]oxyme...)
Affinity DataIC50:  16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591496(CHEMBL5204432)
Affinity DataIC50:  17nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558532(US11365192, Example 72-9)
Affinity DataIC50:  18nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558360(US11365192, Example 43-14)
Affinity DataIC50:  18nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558223(US11365192, Example 13-3)
Affinity DataIC50:  19nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558215(US11365192, Example 11-2)
Affinity DataIC50:  19nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591519(CHEMBL5174407)
Affinity DataIC50:  19nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558140(US11365192, Example 1-45)
Affinity DataIC50:  19nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558552(US11365192, Example 75-7 | US11365192, Example 75-...)
Affinity DataIC50:  20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558359(US11365192, Example 43-13)
Affinity DataIC50:  21nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558340(US11365192, Example 42-18)
Affinity DataIC50:  21nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591499(CHEMBL5173608)
Affinity DataIC50:  21nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558236(N-[6-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxy]hexyl]m...)
Affinity DataIC50:  22nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558362(US11365192, Example 43-16)
Affinity DataIC50:  22nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558173(4-[8-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxy]octyl]-...)
Affinity DataIC50:  24nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558324(US11365192, Example 42-2)
Affinity DataIC50:  25nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558220(US11365192, Example 12-3)
Affinity DataIC50:  25nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558467(US11365192, Example 70-5)
Affinity DataIC50:  27nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558343(US11365192, Example 42-21)
Affinity DataIC50:  28nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558336(US11365192, Example 42-14)
Affinity DataIC50:  30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558357(US11365192, Example 43-11)
Affinity DataIC50:  32nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558309(2,2-Dimethyl-5-[3-[[6-(1H-pyrazol-5-yl)-3-pyridiny...)
Affinity DataIC50:  32nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558186(7-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxymethyl]-5,6...)
Affinity DataIC50:  33nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558411(US11365192, Example 45-42)
Affinity DataIC50:  34nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 495 total ) | Next | Last >>
Jump to: